The glucagon-like peptide-1 receptor agonist family together with the renal sodium/glucose cotransporter-2 inhibitors have garnered interest as potential therapeutic agents for subjects with type 2 diabetes and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.